Unfortunately had to leave at this point to catch my flight home to EU.
It is a pitty, that this important panel discussion is scheduled on the very last day of the conference.
personal takeaways:
M. Tartaglia: who are the caregivers: the daughters / daughters in law. Example: CDR - we know that this endpoint is differently answered by male and female.
Call of actions:
P. Ferrell - lets make this priority. It is priority for our patients, for the loved ones. however, needs to be much broader priority. We have a community that are counting on us.
#Alzheimer #CTAD22 round table - where are we in 2030?
P. Scheltens: will see many more therapies - also small molecules. Screening will be important. Biomarkes may become so good, that we may measure that 10 years in advance.
H. Fillit: 75% in the pipeline are not amyloid/tau targeted and I hope that some may succeed, hope to see advances. Combination therapies. This may extent to antiinflammatory drugs - the same way than cancer developments.
#CTAD22 round table:
Remarkable statement by H. Fillit (#Alzheimer Drug Discovery Foundation, NY):
Lets go to the 80s - if we dont have a RR cuff, there had not been development of antihypertensives. Biomarkers are important. We have to go beyond Amyloid and Tau, into inflammation as well.
Have the blood biomarkers gone fare enough that we do not need brain scans anymore?
Also can digital tests or retinal screening even have us not need to do CSF, and radiology anymore?
Within oral discussion #Lecanemab being quoted as eventually less efective in women and younger patients.
van Dyck discusses that: this is a sub group analysis. Are younger patients and women - CDR overlaps. These are forrest plots, so it is not correct if people walk away and think Lecanemab less works with women or younger. #CTAD22 #Alzheimers
Walter Struhal